Whilst renal dysfunction, especially mild impairment (60<eGFR<90 ml/min), has been often described in HIV-infected population, its potential contribution to HIV evolution and risk of cerebro-cardiovascular disease (CCVD) has not been clarified. Data from HIV-1 infected patients enrolled in the Italian Cohort of Antiretroviral-Naïve (Icona) Foundation Study collected between January 2000 and Feb...

INTRODUCTION Serious non-AIDS events (SNAE) are frequent in HIV patients receiving cART. Current CD4 count was shown to be more strongly associated with infective compared to not-infective SNAE and unable to predict cardiovascular events. We investigated the relationship between baseline and current CD4 count and the risk of both infective and non-infective SNAE in HIV-positive patients accordi...

rai eff ex Un ex me wi eff co we an loc wh oth ad rat rep the dis ro W str [2 stu ha ov ra un an in to to im re Un s.iw W Abstract—Un ilway field is ffective operatio xtensively for niversity of Hu xamine the effe easurement und ithout contamin ffect of dry, w ontaminants such ear measuremen n optical profilo cation with high hich both water her damage we ddition of sand tes increased u plica m...

In Italy the prevalence of recent HIV infection (RHI) isn't currently monitored. Early diagnosis is crucial to allow introduction of antiretroviral therapy (cART) in the recent phase of infection. We aimed to estimate the proportion and the determinants of RHI among patients enrolled in the ICONA cohort; we explored differences in the median time from HIV diagnosis to cART initiation and in the...

INTRODUCTION Emtricitabine/rilpivirine/tenofovir (EVP) is a fixed-dose combination of antiretrovirals (ARV) approved by the European Medicines Agency in November 2011 and introduced in Italy in February 2013. It is a once-a-day single tablet and is licensed in Europe for use only in ARV-naïve patients with a viral load (VL) ≤100,000 copies/mL. OBJECTIVE To identify factors that may be associa...

INTRODUCTION In a recent clinical trial (ACTG 5257), no difference in viral failure (VF) of a first-line cART containing atazanavir/r (ATV/r) or darunavir/r (DRV/r) was found [1]. For the endpoint of discontinuation due to intolerance, the regimen with DRV/r was superior to that of ATV/r (49% of the stops of ATV/r were attributed to jaundice or hyperbilirubinemia). These and other intolerances ...

During the last ten years important achievements have been made throughout the world in the fight against infectious diseases, particularly those preventable by vaccination. the combined efforts of researchers, industry and health workers have made it possible to fully exploit the potential of the new vaccines, using them in the most rational way possible on the basis of the latest epidemiologi...

INTRODUCTION Vaccines able to prevent invasive bacterial diseases have been introduced into national and/or regional immunization plans through different strategies. We evaluated Haemophilus influenzae type b, Pneumococcus and Meningococcus C vaccination coverage in the 5 Ligurian Local Health Agencies, in the Liguria Region, and in Italy in order to assess the efficacy of current immunisation ...

nance of appropriate databases and they enable the cohort to develop a scientific agenda on epidemiological aspects and innovative methodological approaches to help address relevant questions. Collaborations with virologists, immunologists, and pharmacologists are also very important to develop a true multidisciplinary approach of the scientific agenda, with complementary skills and experience,...